Holen Sie sich die Stockscreener-App
151.58
5.61%
8.05
Vorhandelsmarkt:
152.99
1.41
+0.93%
Schlusskurs vom Vortag:
$143.53
Offen:
$146.75
24-Stunden-Volumen:
1.73M
Relative Volume:
1.81
Marktkapitalisierung:
$15.11B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
51.38
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+9.79%
1M Leistung:
+5.26%
6M Leistung:
+26.13%
1J Leistung:
+18.51%
1-Tages-Spanne:
$146.00
$153.54
1-Wochen-Bereich:
$137.83
$153.54
52-Wochen-Spanne:
$84.23
$157.67
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
151.58 | 14.31B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
127.69 | 56.36B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.52 | 45.81B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.76 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.32 | 28.67B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
488.43 | 20.92B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication - Yahoo Finance
Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now - sharewise.com
Does Neurocrine Biosciences’ 9.8% Jump Signal a New Valuation Opportunity in 2025? - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
Neurocrine Biosciences Insider Sold Shares Worth $2,150,513, According to a Recent SEC Filing - MarketScreener
Neurocrine Biosciences Director Sells 15,000 Shares - TradingView
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut - Investing.com Australia
Neurocrine Bio. stock rises as Stifel sees positive IRA impact from Austedo price cut By Investing.com - Investing.com South Africa
Gimme shelter: Neurocrine, Lilly spared in CMS price cut fallout - BioWorld MedTech
Neurocrine Extends Eiry W. Roberts’ Employment Term - The Globe and Mail
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting - MSN
Neurocrine's collaboration for pipeline and market expansion - MarketScreener
[8-K] NEUROCRINE BIOSCIENCES INC Reports Material Event | NBIX SEC FilingForm 8-K - Stock Titan
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - Markets Financial Content
Neurocrine review highlights key differences between tardive dyskinesia drugs - Indian Pharma Post
Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments By Investing.com - Investing.com Canada
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Neurocrine Biosciences Inc Stock Analysis and ForecastEarnings Forecast Updates & High Yield Investment Portfolio - earlytimes.in
A Look at Neurocrine Biosciences (NBIX) Valuation After Setback in Depression Drug Trial - simplywall.st
What analysts say about Neurocrine Biosciences Inc stockMarket Depth Overview & Small Budget Big Profits - earlytimes.in
Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments - Investing.com
Neurocrine study highlights differences between tardive dyskinesia drugs - StreetInsider
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules - Prime Publishers, Inc.
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusPrice Action & AI Forecasted Entry/Exit Points - newser.com
How Neurocrine Biosciences Inc. stock reacts to bond yieldsFed Meeting & Weekly Momentum Picks - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityPortfolio Performance Summary & AI Driven Price Forecasts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfoliosWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investorsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growth2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Measuring Neurocrine Biosciences Inc.’s beta against major indicesJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
How to build a dashboard for Neurocrine Biosciences Inc. stockJuly 2025 Analyst Calls & Verified Stock Trade Ideas - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changes2025 Institutional Moves & Fast Exit Strategy with Risk Control - newser.com
A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further - Seeking Alpha
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):